- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00057577
Prevention of Recurrence in Depression With Drugs and CT (CPT3)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
It is commonly believed that the combination of ADM and psychotherapy is more effective in treating depression than either treatment alone. Data indicate that CT enhances the initial effects of ADM, but little research has been conducted to determine whether prior exposure to CT prevents the onset of new depressive episodes. This study will determine the effectiveness of adding CT to ADM for the treatment of depression.
Participants are randomly assigned to receive either ADM alone or ADM plus CT for up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue cognitive therapy; all recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush Medical Center - Treatment Research Unit
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Depression Research Unit, University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Vanderbilt Adult Outpatient Psychiatry
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Recurrent or chronic major depressive disorder
Exclusion Criteria:
- Current diagnosis of psychotic affective disorder
- History of nonaffective psychotic disorder
- Substance dependence last three months requiring detox
- Schizotypal, antisocial, or borderline personality disorder
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Cognitive therapy plus medications
Participants will receive antidepressant medication plus cognitive therapy
|
CT sessions occur weekly during acute treatment and monthly during continuation.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery.
At recovery, patients receiving combined treatment discontinue CT.
Otros nombres:
Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery.
All recovered patients are randomized a second time to either maintenance medication or medication withdrawal.
Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Otros nombres:
|
Experimental: Medications alone
Participants will receive maintenance of antidepressant medication alone
|
Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery.
All recovered patients are randomized a second time to either maintenance medication or medication withdrawal.
Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants in Remission According to the Longitudinal Interval Follow-up Evaluation (LIFE) and the Hamilton Rating Scale for Depression (HRSD)
Periodo de tiempo: Through month 18 of treatment
|
Remission defined as four consecutive weeks of LIFE Problem Symptom Rating (PSR) values of 2 or less and HRSD scores of 8 or less for four consecutive weeks (with partial remission defined as LIFE PSR values of 3 or less and HRSD scores of 12 or less after month 12 only)
|
Through month 18 of treatment
|
Number of Participants in Recovery According to the LIFE and HRSD
Periodo de tiempo: Through 36 months of treatment
|
Six consecutive months following remission without relapse (two weeks of elevated LIFE PSR scores of 4 or more and HRSD scores of 14 and above)
|
Through 36 months of treatment
|
Number of Participants in Recurrence According to the LIFE and HRSD
Periodo de tiempo: Measured up to Month 36 from recovery
|
Recurrence defined as two consecutive weeks of elevated LIFE PSR scores of 5 or above and HRSD scores of 16 or above (three weeks during period of medication withdrawal)
|
Measured up to Month 36 from recovery
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Serious Adverse Events
Periodo de tiempo: Throughout study, up to 54 months
|
Number Serious Adverse Events (SAEs) as reported to the Institutional Review Boards and Data Safety Monitoring Board throughout the duration of the study
|
Throughout study, up to 54 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Steven D. Hollon, PhD, Vanderbilt University
- Investigador principal: Jan A. Fawcett, MD, Rush Medical Center
Publicaciones y enlaces útiles
Publicaciones Generales
- Khazanov GK, Xu C, Hollon SD, DeRubeis RJ, Thase ME. Adding cognitive therapy to antidepressant medications decreases suicidal ideation. J Affect Disord. 2021 Feb 15;281:183-191. doi: 10.1016/j.jad.2020.12.032. Epub 2020 Dec 8.
- Khazanov GK, Xu C, Dunn BD, Cohen ZD, DeRubeis RJ, Hollon SD. Distress and anhedonia as predictors of depression treatment outcome: A secondary analysis of a randomized clinical trial. Behav Res Ther. 2020 Feb;125:103507. doi: 10.1016/j.brat.2019.103507. Epub 2019 Oct 31.
- DeRubeis RJ, Zajecka J, Shelton RC, Amsterdam JD, Fawcett J, Xu C, Young PR, Gallop R, Hollon SD. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 Mar 1;77(3):237-245. doi: 10.1001/jamapsychiatry.2019.3900. Erratum In: JAMA Psychiatry. 2020 Jan 29;:
- Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Oct;71(10):1157-64. doi: 10.1001/jamapsychiatry.2014.1054.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- R01MH060713 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cognitive Therapy
-
NeuroTronik Inc.DesconocidoInsuficiencia cardiaca | Insuficiencia cardíaca agudaParaguay
-
NeuroTronik Inc.DesconocidoTerapia de estimulación autónoma del gasto cardíaco para la insuficiencia cardíaca aguda (COAST-AHF)Insuficiencia cardíaca agudaPanamá
-
University of Roma La SapienzaTerminadoImplante dental fallido | Mucositis BucalItalia
-
Vyaire MedicalAún no reclutandoSíndrome de insuficiencia respiratoria del recién nacidoItalia
-
Abbott Medical DevicesTerminadoFibrilación auricular paroxísticaAustralia, Alemania, Francia, Italia, Portugal, Reino Unido
-
Boston Children's HospitalTerminadoEstrés Psicológico | Problema de aculturaciónEstados Unidos
-
Abbott Medical DevicesTerminadoFlutter auricular típicoEstados Unidos, Canadá
-
Abbott Medical DevicesTerminado
-
Northwestern UniversityNeuroneticsTerminadoDepresión | Ansiedad | Cáncer en remisión (cualquier tipo o etapa)Estados Unidos